New York City-based Mount Sinai Health System will extend its partnership with Tarrytown, N.Y.-based Regeneron Pharmaceuticals to perform genome sequencing on 33,000 DNA and plasma samples held at the health system.
The health system's BioMe Biotank maintains one of the largest collections of DNA and plasma sample collections in the nation.
Under the terms of the agreement, Regeneron Pharmaceuticals will perform genome sequencing to discover actionable insights about human diseases that may then be applied to drug discovery and development to create more effective therapies for patients.
"The Mount Sinai BioMe Biobank is distinguished by its rich diversity in patient populations linked to electronic medical records," said Judy Cho, MD, professor and director of the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai. "We are extremely pleased to enter into this collaboration with the RGC to develop high-quality sequence data from the BioMe cohort. This partnership provides an important means of more effectively personalizing medical care throughout the Mount Sinai Health System."